HTL Biotechnology inaugurates a new production line dedicated to sterile Hyaluronic Acid
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
An experienced healthcare executive and expert in HTL’s therapeutic areas, in particular dermatology and medical aesthetics, François Fournier brings more than 20 years’ experience in corporate strategy, business execution, and international leadership.
Prior to joining HTL, François Fournier, of French and American nationality, worked in many
countries and several continents in different management positions at pharmaceutical companies,
including most recently at Virbac (as president and CEO of Virbac North America based in Dallas) and previously at Smith & Nephew and Galderma.
Read more below
We’re pleased to share our second CSR report, highlighting the actions and commitments we carried out throughout 2024.
A Global Scientific Gathering Dedicated to Hyaluronic Acid Innovation.
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.